Investigational drug · Phase 2
VG2025
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Intrahepatic Cholangiocarcinoma, Colorectal Cancer With Hepatic Metastases.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "VG2025"
First trial start
2026
Mar 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VG2025", any sponsor or status.
Conditions studied
As listed on its trial records.
- Intrahepatic Cholangiocarcinoma
- Colorectal Cancer With Hepatic Metastases
Approved drugs for the same conditions: Colorectal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "VG2025" as an intervention, largest first.
- A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver MetastasesNot yet recruiting
AkesoIndustry
NCT07357220 · 72 participants (planned) · Start Mar 2, 2026 · Primary completion Feb 28, 2027
Drug: VG2025; AK112 · For: Colorectal Cancer With Hepatic Metastases
Sites: Hangzhou, China
Virogin Biotech Ltd.Industry
NCT07682870 · 42 participants (planned) · Start Nov 11, 2026 · Primary completion Dec 2, 2028
Drug: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection · For: Advanced Malignant Solid Tumor
Sites: Shanghai, China
- A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic CholangiocarcinomaRecruiting
Virogin Biotech Ltd.Industry
NCT07522476 · 30 participants (planned) · Start Aug 25, 2026 · Primary completion Jan 18, 2028
Drug: VG2025 · For: Intrahepatic Cholangiocarcinoma
Sites: Hangzhou, China
Shanghai Virogin Biotech Co., Ltd.Industry
NCT05477849 · 30 participants (planned) · Start Aug 23, 2022 · Primary completion Oct 31, 2025
Drug: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection · For: Advanced Malignant Solid Tumor
Sites: Hangzhou, China
Virogin Biotech Canada LtdIndustry
NCT05266612 · 12 participants (planned) · Start Nov 9, 2022 · Primary completion Dec 31, 2024
Drug: VG2025; Nivolumab Injection [Opdivo] · For: Solid Tumor
Sites: Gilbert, Arizona; Houston, Texas
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06365918 · 0 participants · Start Sep 30, 2024 · Primary completion Oct 2, 2024
Drug: VG2025 · For: Advanced Solid Tumor; Carcinomatosis
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1.
Chouljenko DV, Murad YM, Lee IF, et al. · Mol Ther Oncolytics 2023
Also in development for Intrahepatic Cholangiocarcinoma
- certepetideCEND-1, LSTA1Phase 21 trial
Lisata Therapeutics, Inc. · Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma
- MIV-818Phase 21 trial
Medivir · Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.